
Boston Scientific (BSX) Stock
Boston Scientific Chart
Company Profile
Price: $106.11
Market Cap: $156.39B
Exchange: NYSE
CEO: Mr. Michael F. Mahoney
Sector: Healthcare
Industry: Medical - Devices
Employees: 48.00K
Headquarters: Marlborough, MA
Website: Boston Scientific
Business Summary
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Boston Scientific News
What's Behind The 130% Rise In BSX Stock?
Boston Scientific stock (NYSE: BSX) has gained 3% in the five days since its Q4 earnings report last week. Although the company exceeded expectations with both its results and guidance, the modest stock increase may be due to the significant price appreciation ahead of the earnings announcement.

Boston Scientific Corporation (BSX) Q4 2024 Earnings Call Transcript
Boston Scientific Corporation (NYSE:BSX ) Q4 2024 Earnings Conference Call February 5, 2025 8:00 AM ET Company Participants Jonathan Monson - SVP, IR Michael Mahoney - Chairman and CEO Daniel Brennan - EVP and CFO Kenneth Stein - Chief Medical Officer Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Frederick Wise - Stifel Joanne Wuensch - Citibank David Roman - Goldman Sachs Travis Steed - Bank of America Patrick Wood - Morgan Stanley Danielle Antalffy - UBS Michael Polark - Wolfe Research Vijay Kumar - Evercore ISI Pito Chickering - Deutsche Bank Joshua Jennings - TD Cowen Chris Pasquale - Nephron Research Operator Good morning, and welcome to the Boston Scientific Fourth Quarter 2024 Earnings Call. All participants will be listen-only mode.

Boston Scientific (BSX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Boston Scientific (BSX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Boston Scientific announces results for fourth quarter and full year 2024
MARLBOROUGH, Mass. , Feb. 5, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.561 billion during the fourth quarter of 2024, growing 22.4 percent on a reported basis, 23.1 percent on an operational1 basis and 19.5 percent on an organic2 basis, all compared to the prior year period.

PBH vs. BSX: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Products sector might want to consider either Prestige Consumer Healthcare (PBH) or Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?

What Analyst Projections for Key Metrics Reveal About Boston Scientific (BSX) Q4 Earnings
Evaluate the expected performance of Boston Scientific (BSX) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Late-breaking data presented at AF Symposium 2025 highlight key Boston Scientific therapies for management of patients with atrial fibrillation
First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSEâ„¢ Pulsed Field Ablation System Sub-analysis from OPTION clinical trial highlights consistent safety and efficacy outcomes with the WATCHMAN FLXâ„¢ Left Atrial Appendage Closure Device post cardiac ablation in both concomitant and sequential procedures MARLBOROUGH, Mass. , Jan. 16, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced data supporting the use of the FARAPULSEâ„¢ Pulsed Field Ablation (PFA) System* and the WATCHMAN FLXâ„¢ Left Atrial Appendage Closure (LAAC) Device, respectively, during a late-breaking science session at AF Symposium 2025.

PBH or BSX: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?

Boston Scientific Earnings
This section highlights Boston Scientific's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
---|---|---|---|---|---|
Read Transcript | Q4 | 2024 | 2025-02-05 | $0.66 | $0.70 |
Read Transcript | Q3 | 2024 | 2024-10-23 | $0.59 | $0.63 |
Read Transcript | Q2 | 2024 | 2024-07-24 | $0.58 | $0.62 |
Read Transcript | Q1 | 2024 | 2024-04-24 | $0.51 | $0.56 |
Read Transcript | Q4 | 2023 | 2024-01-31 | $0.51 | $0.55 |
Read Transcript | Q3 | 2023 | 2023-10-26 | $0.48 | $0.50 |
Read Transcript | Q2 | 2023 | 2023-07-27 | $0.49 | $0.53 |
Read Transcript | Q1 | 2023 | 2023-04-26 | $0.43 | $0.47 |
Financial Statements
Access annual & quarterly financial statements for Boston Scientific, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|
Revenue | $14.24B | $12.68B | $11.89B | $9.91B | $10.73B |
Cost of Revenue | $4.34B | $4.00B | $3.76B | $3.51B | $3.18B |
Gross Profit | $9.89B | $8.68B | $8.13B | $6.40B | $7.55B |
Gross Profit Ratio | 69.49% | 68.44% | 68.37% | 64.59% | 70.37% |
Research and Development Expenses | $1.41B | $1.32B | $1.20B | $1.14B | $1.17B |
General and Administrative Expenses | $- | $- | $- | $- | $- |
Selling and Marketing Expenses | $- | $- | $- | $- | $- |
Selling General and Administrative Expenses | $5.19B | $4.52B | $4.36B | $3.79B | $3.94B |
Other Expenses | $948.00M | $803.00M | $741.00M | $789.00M | $699.00M |
Operating Expenses | $7.55B | $6.65B | $6.30B | $5.72B | $5.81B |
Cost and Expenses | $11.90B | $10.65B | $10.06B | $9.23B | $8.99B |
Interest Income | $22.00M | $10.00M | $4.00M | $3.00M | $30.00M |
Interest Expense | $265.00M | $470.00M | $341.00M | $361.00M | $473.00M |
Depreciation and Amortization | $1.20B | $1.14B | $1.09B | $1.12B | $1.01B |
EBITDA | $3.45B | $2.74B | $2.52B | $1.51B | $2.21B |
EBITDA Ratio | 24.25% | 22.08% | 23.42% | 18.49% | 19.39% |
Operating Income | $2.34B | $1.65B | $2.04B | $1.04B | $1.52B |
Operating Income Ratio | 16.45% | 13.00% | 17.19% | 10.53% | 14.14% |
Total Other Income Expenses Net | $-358.00M | $-508.00M | $-123.00M | $-1.12B | $-831.00M |
Income Before Tax | $1.99B | $1.14B | $1.08B | $-138.00M | $687.00M |
Income Before Tax Ratio | 13.94% | 9.00% | 9.05% | -1.39% | 6.40% |
Income Tax Expense | $393.00M | $443.00M | $36.00M | $2.00M | $-4.01B |
Net Income | $1.59B | $698.00M | $1.04B | $-140.00M | $4.70B |
Net Income Ratio | 11.19% | 5.50% | 8.76% | -1.41% | 43.78% |
EPS | $1.08 | $0.45 | $0.69 | $-0.10 | $3.38 |
EPS Diluted | $1.07 | $0.45 | $0.69 | $-0.10 | $3.33 |
Weighted Average Shares Outstanding | 1.45B | 1.43B | 1.42B | 1.42B | 1.39B |
Weighted Average Shares Outstanding Diluted | 1.46B | 1.44B | 1.43B | 1.42B | 1.41B |
SEC Filing | Source | Source | Source | Source | Source |
Income Statement Charts
Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $4.21B | $4.12B | $3.86B | $3.73B | $3.53B | $3.60B | $3.39B | $3.24B | $3.17B | $3.24B | $3.03B | $3.13B | $2.93B | $3.08B | $2.75B | $2.71B | $2.66B | $2.00B | $2.54B | $2.90B |
Cost of Revenue | $1.31B | $1.53B | $1.21B | $1.15B | $1.11B | $1.07B | $1.04B | $1.02B | $990.00M | $1.02B | $967.00M | $982.00M | $914.00M | $957.00M | $906.00M | $1.01B | $881.00M | $799.00M | $818.00M | $868.00M |
Gross Profit | $2.90B | $2.58B | $2.65B | $2.58B | $2.42B | $2.53B | $2.35B | $2.22B | $2.18B | $2.22B | $2.06B | $2.15B | $2.02B | $2.12B | $1.85B | $1.69B | $1.78B | $1.20B | $1.73B | $2.04B |
Gross Profit Ratio | 68.83% | 62.74% | 68.65% | 69.21% | 68.47% | 70.27% | 69.31% | 68.41% | 68.77% | 68.50% | 68.04% | 68.60% | 68.83% | 68.90% | 67.08% | 62.56% | 66.87% | 60.11% | 67.83% | 70.12% |
Research and Development Expenses | $407.00M | $383.00M | $366.00M | $363.00M | $356.00M | $359.00M | $337.00M | $330.00M | $339.00M | $335.00M | $319.00M | $320.00M | $310.00M | $298.00M | $276.00M | $286.00M | $315.00M | $242.00M | $300.00M | $309.00M |
General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.03B | $984.00M | $798.00M | $978.00M | $1.09B |
Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Selling General and Administrative Expenses | $1.56B | $1.45B | $1.36B | $1.38B | $1.24B | $1.35B | $1.22B | $1.16B | $1.13B | $1.17B | $1.06B | $1.15B | $1.07B | $1.12B | $1.02B | $1.03B | $984.00M | $798.00M | $978.00M | $1.09B |
Other Expenses | $195.00M | $-9.00M | $-224.00M | $64.00M | $-18.00M | $-18.00M | $214.00M | $199.00M | $202.00M | $204.00M | $198.00M | $26.00M | $181.00M | $-26.00M | $37.00M | $352.00M | $64.00M | $-18.00M | $-36.00M | $-37.00M |
Operating Expenses | $2.16B | $1.84B | $1.95B | $1.96B | $1.81B | $1.92B | $1.77B | $1.69B | $1.67B | $1.70B | $1.58B | $1.67B | $1.56B | $1.60B | $1.48B | $1.51B | $1.50B | $1.24B | $1.48B | $1.60B |
Cost and Expenses | $3.48B | $3.37B | $3.16B | $3.11B | $2.92B | $2.99B | $2.81B | $2.72B | $2.66B | $2.73B | $2.54B | $2.65B | $2.47B | $2.56B | $2.39B | $2.52B | $2.38B | $2.04B | $2.30B | $2.47B |
Interest Income | $- | $- | $- | $22.00M | $66.00M | $70.00M | $65.00M | $4.00M | $1.00M | $1.00M | $4.00M | $1.00M | $1.00M | $1.00M | $1.00M | $- | $1.00M | $- | $1.00M | $1.00M |
Interest Expense | $79.00M | $77.00M | $69.00M | $65.00M | $66.00M | $70.00M | $65.00M | $64.00M | $63.00M | $64.00M | $279.00M | $87.00M | $86.00M | $86.00M | $82.00M | $96.00M | $86.00M | $91.00M | $88.00M | $179.00M |
Depreciation and Amortization | $306.00M | $311.00M | $304.00M | $313.00M | $301.00M | $298.00M | $285.00M | $294.00M | $284.00M | $284.00M | $274.00M | $290.00M | $272.00M | $263.00M | $268.00M | $194.00M | $282.00M | $275.00M | $277.00M | $201.00M |
EBITDA | $1.05B | $812.00M | $984.00M | $883.00M | $976.00M | $795.00M | $796.00M | $757.00M | $593.00M | $692.00M | $725.00M | $498.00M | $841.00M | $500.00M | $682.00M | $597.00M | $145.00M | $191.00M | $392.00M | $374.00M |
EBITDA Ratio | 25.04% | 25.68% | 25.96% | 27.28% | 22.71% | 22.17% | 21.95% | 24.21% | 20.79% | 21.86% | 21.45% | 22.35% | 28.10% | 21.90% | 21.40% | 27.07% | 20.46% | 7.19% | 16.16% | 20.62% |
Operating Income | $733.00M | $747.00M | $693.00M | $584.00M | $693.00M | $514.00M | $552.00M | $586.00M | $358.00M | $423.00M | $466.00M | $180.00M | $387.00M | $262.00M | $370.00M | $-8.00M | $-205.00M | $-71.00M | $146.00M | $210.00M |
Operating Income Ratio | 17.42% | 18.13% | 17.97% | 15.68% | 19.65% | 14.28% | 16.29% | 18.08% | 11.29% | 13.04% | 15.40% | 5.76% | 13.20% | 8.51% | 13.44% | -0.30% | -7.71% | -3.54% | 5.74% | 7.23% |
Total Other Income Expenses Net | $-64.00M | $-100.00M | $-67.00M | $-79.00M | $-83.00M | $-88.00M | $-108.00M | $-53.00M | $-113.00M | $-78.00M | $-310.00M | $-61.00M | $96.00M | $-113.00M | $-45.00M | $-386.00M | $-22.00M | $-110.00M | $-124.00M | $-216.00M |
Income Before Tax | $669.00M | $420.00M | $608.00M | $505.00M | $610.00M | $426.00M | $444.00M | $396.00M | $245.00M | $345.00M | $156.00M | $120.00M | $483.00M | $149.00M | $325.00M | $248.00M | $-227.00M | $-181.00M | $22.00M | $-6.00M |
Income Before Tax Ratio | 15.89% | 10.19% | 15.77% | 13.56% | 17.30% | 11.84% | 13.10% | 12.21% | 7.73% | 10.64% | 5.16% | 3.84% | 16.47% | 4.84% | 11.81% | 9.16% | -8.54% | -9.04% | 0.87% | -0.21% |
Income Tax Expense | $200.00M | $98.00M | $115.00M | $1.00M | $105.00M | $156.00M | $131.00M | $256.00M | $57.00M | $85.00M | $45.00M | $26.00M | $64.00M | $-37.00M | $-16.00M | $96.00M | $-72.00M | $-33.00M | $12.00M | $-4.00B |
Net Income | $468.00M | $324.00M | $492.00M | $505.00M | $504.00M | $270.00M | $314.00M | $140.00M | $174.00M | $246.00M | $96.00M | $82.00M | $405.00M | $172.00M | $327.00M | $152.00M | $-155.00M | $-147.00M | $11.00M | $4.00B |
Net Income Ratio | 11.12% | 7.86% | 12.76% | 13.56% | 14.29% | 7.50% | 9.27% | 4.32% | 5.49% | 7.58% | 3.17% | 2.62% | 13.81% | 5.59% | 11.88% | 5.61% | -5.83% | -7.34% | 0.43% | 137.56% |
EPS | $0.32 | $0.22 | $0.34 | $0.34 | $0.34 | $0.18 | $0.21 | $0.09 | $0.12 | $0.17 | $0.07 | $0.07 | $0.29 | $0.13 | $0.24 | $0.11 | $-0.11 | $-0.11 | $0.01 | $2.87 |
EPS Diluted | $0.32 | $0.22 | $0.33 | $0.34 | $0.34 | $0.18 | $0.21 | $0.09 | $0.12 | $0.17 | $0.07 | $0.07 | $0.29 | $0.13 | $0.24 | $0.11 | $-0.11 | $-0.10 | $0.01 | $2.83 |
Weighted Average Shares Outstanding | 1.47B | 1.47B | 1.47B | 1.47B | 1.46B | 1.45B | 1.44B | 1.43B | 1.43B | 1.43B | 1.43B | 1.43B | 1.42B | 1.42B | 1.42B | 1.43B | 1.41B | 1.38B | 1.40B | 1.39B |
Weighted Average Shares Outstanding Diluted | 1.49B | 1.48B | 1.48B | 1.48B | 1.48B | 1.46B | 1.45B | 1.44B | 1.44B | 1.44B | 1.44B | 1.44B | 1.44B | 1.43B | 1.43B | 1.44B | 1.43B | 1.41B | 1.41B | 1.41B |
SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|
Cash and Cash Equivalents | $865.00M | $928.00M | $1.93B | $1.73B | $217.00M |
Short Term Investments | $- | $- | $- | $- | $- |
Cash and Short Term Investments | $865.00M | $928.00M | $1.93B | $1.73B | $217.00M |
Net Receivables | $2.23B | $1.97B | $1.78B | $1.53B | $1.83B |
Inventory | $2.48B | $1.87B | $1.61B | $1.35B | $1.58B |
Other Current Assets | $937.00M | $995.00M | $1.00B | $2.08B | $1.07B |
Total Current Assets | $6.51B | $5.76B | $6.32B | $6.69B | $4.70B |
Property Plant Equipment Net | $3.30B | $2.83B | $2.69B | $2.54B | $2.42B |
Goodwill | $14.39B | $12.92B | $11.99B | $9.95B | $10.18B |
Intangible Assets | $6.00B | $5.90B | $6.12B | $5.92B | $7.89B |
Goodwill and Intangible Assets | $20.39B | $18.82B | $18.11B | $15.87B | $18.06B |
Long Term Investments | $413.00M | $407.00M | $412.00M | $918.00M | $458.00M |
Tax Assets | $3.84B | $3.94B | $4.14B | $4.21B | $4.20B |
Other Non-Current Assets | $680.00M | $707.00M | $563.00M | $545.00M | $735.00M |
Total Non-Current Assets | $28.62B | $26.71B | $25.91B | $24.08B | $25.87B |
Other Assets | $- | $- | $2.00M | $3.00M | $- |
Total Assets | $35.14B | $32.47B | $32.23B | $30.78B | $30.57B |
Account Payables | $942.00M | $862.00M | $794.00M | $513.00M | $542.00M |
Short Term Debt | $531.00M | $20.00M | $261.00M | $13.00M | $1.42B |
Tax Payables | $220.00M | $232.00M | $209.00M | $158.00M | $265.00M |
Deferred Revenue | $266.00M | $220.00M | $208.00M | $138.00M | $144.00M |
Other Current Liabilities | $2.97B | $2.47B | $2.80B | $2.86B | $2.50B |
Total Current Liabilities | $4.93B | $3.80B | $4.27B | $3.68B | $4.87B |
Long Term Debt | $8.96B | $9.26B | $9.19B | $9.53B | $8.87B |
Deferred Revenue Non-Current | $311.00M | $289.00M | $276.00M | $257.00M | $1.20B |
Deferred Tax Liabilities Non-Current | $134.00M | $144.00M | $310.00M | $330.00M | $595.00M |
Other Non-Current Liabilities | $1.27B | $1.40B | $1.55B | $1.66B | $2.36B |
Total Non-Current Liabilities | $10.67B | $11.09B | $11.33B | $11.77B | $11.82B |
Other Liabilities | $- | $- | $- | $- | $- |
Total Liabilities | $15.61B | $14.90B | $15.61B | $15.45B | $16.69B |
Preferred Stock | $- | $- | $- | $- | $- |
Common Stock | $17.00M | $17.00M | $17.00M | $17.00M | $16.00M |
Retained Earnings | $819.00M | $-750.00M | $-1.39B | $-2.38B | $-2.25B |
Accumulated Other Comprehensive Income Loss | $49.00M | $269.00M | $263.00M | $207.00M | $270.00M |
Other Total Stockholders Equity | $18.40B | $18.04B | $17.73B | $17.48B | $15.84B |
Total Stockholders Equity | $19.28B | $17.57B | $16.62B | $15.33B | $13.88B |
Total Equity | $19.53B | $17.57B | $16.62B | $15.33B | $13.88B |
Total Liabilities and Stockholders Equity | $34.89B | $32.47B | $32.23B | $30.78B | $30.57B |
Minority Interest | $248.00M | $- | $- | $- | $- |
Total Liabilities and Total Equity | $34.89B | $32.47B | $32.23B | $30.78B | $30.57B |
Total Investments | $413.00M | $407.00M | $412.00M | $918.00M | $458.00M |
Total Debt | $9.49B | $9.28B | $9.45B | $9.54B | $10.28B |
Net Debt | $8.63B | $8.35B | $7.53B | $7.80B | $10.06B |
Balance Sheet Charts
Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash and Cash Equivalents | $2.50B | $2.99B | $2.33B | $865.00M | $952.00M | $426.00M | $570.00M | $928.00M | $338.00M | $276.00M | $325.00M | $1.93B | $1.95B | $2.67B | $2.02B | $1.73B | $2.02B | $1.72B | $370.00M | $217.00M |
Short Term Investments | $- | $- | $1.73B | $- | $- | $- | $- | $- | $- | $- | $7.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Cash and Short Term Investments | $2.50B | $2.99B | $2.33B | $865.00M | $952.00M | $426.00M | $570.00M | $928.00M | $338.00M | $276.00M | $325.00M | $1.93B | $1.95B | $2.67B | $2.02B | $1.73B | $2.02B | $1.72B | $370.00M | $217.00M |
Net Receivables | $2.50B | $2.40B | $2.30B | $2.23B | $2.10B | $2.13B | $2.08B | $1.97B | $1.87B | $1.92B | $1.87B | $1.78B | $1.67B | $1.68B | $1.63B | $1.53B | $1.60B | $1.46B | $1.70B | $1.83B |
Inventory | $2.75B | $2.61B | $2.56B | $2.48B | $2.40B | $2.25B | $2.05B | $1.87B | $1.79B | $1.75B | $1.74B | $1.61B | $1.60B | $1.43B | $1.41B | $1.35B | $1.47B | $1.52B | $1.63B | $1.58B |
Other Current Assets | $1.00B | $1.07B | $991.00M | $937.00M | $1.05B | $1.08B | $1.01B | $995.00M | $1.15B | $1.14B | $1.14B | $1.00B | $1.01B | $978.00M | $1.05B | $2.08B | $1.07B | $1.11B | $1.12B | $1.07B |
Total Current Assets | $8.76B | $8.99B | $8.19B | $6.51B | $6.50B | $5.89B | $5.70B | $5.76B | $5.14B | $5.08B | $5.07B | $6.32B | $6.23B | $6.76B | $6.10B | $6.69B | $6.16B | $5.80B | $4.82B | $4.70B |
Property Plant Equipment Net | $3.50B | $3.37B | $3.33B | $3.30B | $3.08B | $2.98B | $2.88B | $2.83B | $2.66B | $2.65B | $2.69B | $2.69B | $2.52B | $2.49B | $2.46B | $2.54B | $2.38B | $2.39B | $2.42B | $2.42B |
Goodwill | $15.03B | $14.40B | $14.36B | $14.39B | $13.61B | $13.66B | $13.27B | $12.92B | $12.85B | $12.88B | $12.95B | $11.99B | $11.82B | $10.87B | $10.87B | $9.95B | $10.14B | $10.10B | $10.10B | $10.18B |
Intangible Assets | $5.75B | $5.42B | $5.84B | $6.00B | $5.85B | $6.06B | $6.06B | $5.90B | $6.06B | $6.35B | $6.58B | $6.12B | $6.23B | $5.79B | $5.99B | $5.92B | $6.80B | $7.16B | $7.39B | $7.89B |
Goodwill and Intangible Assets | $20.79B | $19.81B | $20.20B | $20.39B | $19.46B | $19.72B | $19.33B | $18.82B | $18.91B | $19.23B | $19.53B | $18.11B | $18.05B | $16.66B | $16.86B | $15.87B | $16.93B | $17.26B | $17.49B | $18.06B |
Long Term Investments | $532.00M | $589.00M | $429.00M | $413.00M | $427.00M | $421.00M | $385.00M | $407.00M | $381.00M | $376.00M | $399.00M | $412.00M | $434.00M | $616.00M | $643.00M | $918.00M | $567.00M | $467.00M | $437.00M | $458.00M |
Tax Assets | $3.82B | $3.80B | $3.79B | $3.84B | $3.84B | $3.87B | $3.90B | $3.94B | $4.02B | $4.06B | $4.10B | $4.14B | $4.05B | $4.04B | $4.17B | $4.21B | $4.17B | $4.18B | $4.16B | $4.20B |
Other Non-Current Assets | $684.00M | $546.00M | $737.00M | $679.00M | $732.00M | $728.00M | $697.00M | $707.00M | $834.00M | $791.00M | $552.00M | $563.00M | $594.00M | $603.00M | $664.00M | $545.00M | $636.00M | $717.00M | $775.00M | $735.00M |
Total Non-Current Assets | $29.32B | $28.12B | $28.48B | $28.62B | $27.54B | $27.72B | $27.19B | $26.71B | $26.80B | $27.10B | $27.27B | $25.91B | $25.65B | $24.41B | $24.80B | $24.08B | $24.68B | $25.02B | $25.29B | $25.87B |
Other Assets | $- | $- | $1.00M | $1.00M | $- | $-1.00M | $-2.00M | $- | $-1.00M | $3.00M | $-2.00M | $2.00M | $- | $1.00M | $- | $3.00M | $1.00M | $-2.00M | $-1.00M | $- |
Total Assets | $38.08B | $37.11B | $36.67B | $35.14B | $34.04B | $33.60B | $32.89B | $32.47B | $31.95B | $32.19B | $32.34B | $32.23B | $31.88B | $31.17B | $30.90B | $30.78B | $30.84B | $30.82B | $30.11B | $30.57B |
Account Payables | $907.00M | $906.00M | $921.00M | $942.00M | $929.00M | $899.00M | $868.00M | $862.00M | $803.00M | $732.00M | $696.00M | $794.00M | $674.00M | $689.00M | $615.00M | $513.00M | $452.00M | $408.00M | $605.00M | $542.00M |
Short Term Debt | $1.65B | $1.58B | $1.08B | $531.00M | $513.00M | $559.00M | $510.00M | $20.00M | $20.00M | $170.00M | $238.00M | $261.00M | $261.00M | $262.00M | $13.00M | $13.00M | $11.00M | $254.00M | $1.00B | $1.42B |
Tax Payables | $332.00M | $224.00M | $257.00M | $220.00M | $352.00M | $400.00M | $281.00M | $232.00M | $234.00M | $257.00M | $459.00M | $209.00M | $113.00M | $121.00M | $151.00M | $158.00M | $37.00M | $193.00M | $246.00M | $265.00M |
Deferred Revenue | $290.00M | $284.00M | $280.00M | $266.00M | $246.00M | $242.00M | $231.00M | $220.00M | $216.00M | $222.00M | $212.00M | $208.00M | $160.00M | $141.00M | $139.00M | $138.00M | $147.00M | $143.00M | $141.00M | $144.00M |
Other Current Liabilities | $2.73B | $2.58B | $2.37B | $2.97B | $2.54B | $2.46B | $2.19B | $2.47B | $2.28B | $2.50B | $2.67B | $2.80B | $2.81B | $2.86B | $2.48B | $2.86B | $2.65B | $2.11B | $1.98B | $2.50B |
Total Current Liabilities | $5.91B | $5.58B | $4.92B | $4.93B | $4.58B | $4.56B | $4.08B | $3.80B | $3.55B | $3.88B | $4.28B | $4.27B | $4.02B | $4.07B | $3.39B | $3.68B | $3.30B | $3.11B | $3.98B | $4.87B |
Long Term Debt | $9.61B | $9.36B | $9.92B | $8.96B | $8.79B | $8.89B | $8.86B | $9.26B | $8.91B | $9.16B | $9.45B | $9.19B | $9.20B | $9.20B | $9.44B | $9.53B | $9.33B | $9.54B | $9.59B | $8.87B |
Deferred Revenue Non-Current | $328.00M | $316.00M | $314.00M | $311.00M | $301.00M | $295.00M | $290.00M | $289.00M | $278.00M | $279.00M | $279.00M | $276.00M | $296.00M | $283.00M | $264.00M | $257.00M | $6.00M | $251.00M | $251.00M | $1.20B |
Deferred Tax Liabilities Non-Current | $138.00M | $132.00M | $132.00M | $134.00M | $91.00M | $135.00M | $210.00M | $144.00M | $278.00M | $265.00M | $261.00M | $310.00M | $274.00M | $115.00M | $336.00M | $330.00M | $522.00M | $585.00M | $589.00M | $595.00M |
Other Non-Current Liabilities | $1.14B | $1.12B | $1.22B | $1.27B | $1.16B | $1.23B | $1.34B | $1.40B | $1.29B | $1.35B | $1.34B | $1.55B | $1.62B | $1.55B | $1.75B | $1.66B | $2.13B | $1.73B | $1.90B | $2.36B |
Total Non-Current Liabilities | $11.21B | $10.92B | $11.59B | $10.67B | $10.34B | $10.55B | $10.70B | $11.09B | $10.76B | $11.05B | $11.33B | $11.33B | $11.39B | $11.15B | $11.79B | $11.77B | $11.98B | $12.10B | $12.33B | $11.82B |
Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Total Liabilities | $17.12B | $16.50B | $16.50B | $15.61B | $14.91B | $15.12B | $14.78B | $14.90B | $14.31B | $14.94B | $15.60B | $15.61B | $15.41B | $15.23B | $15.18B | $15.45B | $15.28B | $15.21B | $16.31B | $16.69B |
Preferred Stock | $- | $- | $18.21B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Common Stock | $17.00M | $17.00M | $17.00M | $17.00M | $17.00M | $17.00M | $17.00M | $17.00M | $17.00M | $17.00M | $17.00M | $17.00M | $17.00M | $17.00M | $17.00M | $17.00M | $17.00M | $17.00M | $16.00M | $16.00M |
Retained Earnings | $2.11B | $1.64B | $1.31B | $819.00M | $315.00M | $-189.00M | $-450.00M | $-750.00M | $-876.00M | $-1.05B | $-1.30B | $-1.39B | $-1.47B | $-1.88B | $-2.05B | $-2.38B | $-2.57B | $-2.40B | $-2.25B | $-2.25B |
Accumulated Other Comprehensive Income Loss | $-128.00M | $164.00M | $132.00M | $49.00M | $231.00M | $208.00M | $178.00M | $269.00M | $532.00M | $433.00M | $222.00M | $263.00M | $238.00M | $237.00M | $254.00M | $207.00M | $151.00M | $131.00M | $168.00M | $270.00M |
Other Total Stockholders Equity | $18.71B | $18.55B | $18.46B | $18.40B | $18.32B | $18.19B | $18.11B | $18.31B | $17.97B | $17.85B | $17.79B | $17.73B | $17.68B | $17.57B | $17.50B | $17.48B | $17.97B | $17.87B | $15.87B | $15.84B |
Total Stockholders Equity | $20.71B | $20.37B | $19.93B | $19.28B | $18.89B | $18.23B | $17.85B | $17.57B | $17.64B | $17.25B | $16.73B | $16.62B | $16.46B | $15.94B | $15.72B | $15.33B | $15.56B | $15.62B | $13.80B | $13.88B |
Total Equity | $20.96B | $20.61B | $20.17B | $19.53B | $19.13B | $18.48B | $18.11B | $17.57B | $17.64B | $17.25B | $16.73B | $16.62B | $16.46B | $15.94B | $15.72B | $15.33B | $15.56B | $15.62B | $13.80B | $13.88B |
Total Liabilities and Stockholders Equity | $38.08B | $37.11B | $36.43B | $34.89B | $33.80B | $33.60B | $32.89B | $32.47B | $31.95B | $32.19B | $32.34B | $32.23B | $31.88B | $31.17B | $30.90B | $30.78B | $30.84B | $30.82B | $30.11B | $30.57B |
Minority Interest | $248.00M | $238.00M | $242.00M | $248.00M | $243.00M | $259.00M | $259.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Total Liabilities and Total Equity | $38.08B | $37.11B | $36.43B | $34.89B | $33.80B | $33.60B | $32.89B | $32.47B | $31.95B | $32.19B | $32.34B | $32.23B | $31.88B | $31.17B | $30.90B | $30.78B | $30.84B | $30.82B | $30.11B | $30.57B |
Total Investments | $532.00M | $589.00M | $1.73B | $413.00M | $427.00M | $421.00M | $385.00M | $407.00M | $381.00M | $376.00M | $406.00M | $412.00M | $434.00M | $616.00M | $643.00M | $918.00M | $567.00M | $467.00M | $437.00M | $458.00M |
Total Debt | $11.26B | $10.94B | $11.00B | $9.49B | $9.30B | $9.45B | $9.37B | $9.28B | $8.93B | $9.33B | $9.68B | $9.45B | $9.46B | $9.46B | $9.44B | $9.54B | $9.33B | $9.79B | $10.60B | $10.28B |
Net Debt | $8.76B | $7.95B | $8.67B | $8.63B | $8.35B | $9.03B | $8.79B | $8.35B | $8.60B | $9.05B | $9.36B | $7.53B | $7.51B | $6.79B | $7.43B | $7.80B | $7.31B | $8.06B | $10.23B | $10.06B |
Annual Cash Flow
Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|
Net Income | $1.59B | $698.00M | $1.04B | $-82.00M | $4.70B |
Depreciation and Amortization | $1.20B | $1.14B | $1.09B | $1.12B | $1.01B |
Deferred Income Tax | $-1.00M | $-63.00M | $-124.00M | $-82.00M | $-4.30B |
Stock Based Compensation | $233.00M | $220.00M | $194.00M | $170.00M | $157.00M |
Change in Working Capital | $-770.00M | $-1.00B | $-351.00M | $42.00M | $-282.00M |
Accounts Receivables | $-238.00M | $-220.00M | $-279.00M | $335.00M | $-130.00M |
Inventory | $-660.00M | $-321.00M | $-346.00M | $-65.00M | $-290.00M |
Accounts Payables | $118.00M | $-255.00M | $408.00M | $88.00M | $111.00M |
Other Working Capital | $10.00M | $-209.00M | $-134.00M | $-316.00M | $27.00M |
Other Non Cash Items | $253.00M | $540.00M | $17.00M | $337.00M | $551.00M |
Net Cash Provided by Operating Activities | $2.50B | $1.53B | $1.87B | $1.51B | $1.84B |
Investments in Property Plant and Equipment | $-711.00M | $-612.00M | $-554.00M | $-376.00M | $-461.00M |
Acquisitions Net | $-1.81B | $-1.54B | $-1.43B | $12.00M | $-4.29B |
Purchases of Investments | $- | $-24.00M | $96.00M | $-146.00M | $-348.00M |
Sales Maturities of Investments | $- | $56.00M | $294.00M | $12.00M | $59.00M |
Other Investing Activities | $-52.00M | $106.00M | $-1.00M | $87.00M | $1.00M |
Net Cash Used for Investing Activities | $-2.57B | $-2.01B | $-1.60B | $-411.00M | $-5.04B |
Debt Repayment | $-4.00M | $-165.00M | $- | $-999.00M | $2.79B |
Common Stock Issued | $182.00M | $- | $110.00M | $975.00M | $123.00M |
Common Stock Repurchased | $182.00M | $136.00M | $110.00M | $-535.00M | $- |
Dividends Paid | $-28.00M | $-55.00M | $-55.00M | $-28.00M | $- |
Other Financing Activities | $37.00M | $-464.00M | $-40.00M | $880.00M | $179.00M |
Net Cash Used Provided by Financing Activities | $5.00M | $-548.00M | $-95.00M | $293.00M | $2.97B |
Effect of Forex Changes on Cash | $-4.00M | $-9.00M | $-6.00M | $-2.00M | $10.00M |
Net Change in Cash | $-71.00M | $-1.04B | $173.00M | $1.39B | $-222.00M |
Cash at End of Period | $1.05B | $1.13B | $2.17B | $2.00B | $607.00M |
Cash at Beginning of Period | $1.13B | $2.17B | $2.00B | $607.00M | $829.00M |
Operating Cash Flow | $2.50B | $1.53B | $1.87B | $1.51B | $1.84B |
Capital Expenditure | $-800.00M | $-612.00M | $-554.00M | $-376.00M | $-461.00M |
Free Cash Flow | $1.70B | $914.00M | $1.32B | $1.13B | $1.38B |
Cash Flow Charts
Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | $700.00M | $324.00M | $493.00M | $504.00M | $504.00M | $270.00M | $314.00M | $140.00M | $188.00M | $260.00M | $110.00M | $95.00M | $419.00M | $186.00M | $341.00M | $210.00M | $-155.00M | $-148.00M | $11.00M | $4.00B |
Depreciation and Amortization | $636.00M | $311.00M | $304.00M | $313.00M | $300.00M | $298.00M | $285.00M | $294.00M | $284.00M | $284.00M | $274.00M | $290.00M | $272.00M | $263.00M | $268.00M | $289.00M | $282.00M | $275.00M | $277.00M | $293.00M |
Deferred Income Tax | $-11.00M | $-10.00M | $31.00M | $73.00M | $-29.00M | $-64.00M | $19.00M | $7.00M | $23.00M | $-18.00M | $-75.00M | $-75.00M | $39.00M | $-87.00M | $-1.00M | $- | $-28.00M | $8.00M | $7.00M | $- |
Stock Based Compensation | $-61.00M | $195.00M | $63.00M | $59.00M | $59.00M | $60.00M | $55.00M | $55.00M | $58.00M | $55.00M | $52.00M | $49.00M | $51.00M | $47.00M | $47.00M | $42.00M | $40.00M | $46.00M | $42.00M | $157.00M |
Change in Working Capital | $523.00M | $-209.00M | $-743.00M | $-57.00M | $-176.00M | $-14.00M | $-523.00M | $334.00M | $-304.00M | $-353.00M | $-682.00M | $-35.00M | $-211.00M | $248.00M | $-353.00M | $-117.00M | $320.00M | $18.00M | $-580.00M | $-393.00M |
Accounts Receivables | $-175.00M | $-114.00M | $-114.00M | $-74.00M | $-3.00M | $-75.00M | $-86.00M | $-44.00M | $-14.00M | $-96.00M | $-66.00M | $-148.00M | $14.00M | $-28.00M | $-117.00M | $93.00M | $-123.00M | $204.00M | $161.00M | $-130.00M |
Inventory | $-89.00M | $-95.00M | $-124.00M | $-59.00M | $-202.00M | $-214.00M | $-185.00M | $-46.00M | $-95.00M | $-72.00M | $-108.00M | $-31.00M | $-215.00M | $15.00M | $-115.00M | $-64.00M | $35.00M | $163.00M | $-199.00M | $-290.00M |
Accounts Payables | $69.00M | $71.00M | $-450.00M | $23.00M | $17.00M | $289.00M | $-211.00M | $335.00M | $-141.00M | $-81.00M | $-368.00M | $133.00M | $-65.00M | $333.00M | $7.00M | $88.00M | $- | $- | $- | $111.00M |
Other Working Capital | $718.00M | $-71.00M | $-55.00M | $53.00M | $12.00M | $-14.00M | $482.00M | $89.00M | $-54.00M | $-104.00M | $-140.00M | $144.00M | $55.00M | $-72.00M | $-128.00M | $-146.00M | $408.00M | $-349.00M | $-542.00M | $27.00M |
Other Non Cash Items | $-785.00M | $1.16B | $14.00M | $65.00M | $40.00M | $108.00M | $40.00M | $-23.00M | $221.00M | $79.00M | $263.00M | $154.00M | $-105.00M | $-14.00M | $-18.00M | $249.00M | $184.00M | $70.00M | $166.00M | $-3.36B |
Net Cash Provided by Operating Activities | $1.00B | $813.00M | $164.00M | $957.00M | $698.00M | $658.00M | $190.00M | $807.00M | $470.00M | $307.00M | $-58.00M | $478.00M | $465.00M | $643.00M | $284.00M | $673.00M | $643.00M | $269.00M | $-77.00M | $692.00M |
Investments in Property Plant and Equipment | $-179.00M | $-155.00M | $-245.00M | $-267.00M | $-206.00M | $-206.00M | $-121.00M | $-200.00M | $-172.00M | $-105.00M | $-131.00M | $-266.00M | $-107.00M | $-106.00M | $-75.00M | $-159.00M | $-150.00M | $-95.00M | $-102.00M | $-186.00M |
Acquisitions Net | $-1.13B | $-48.00M | $-47.00M | $-793.00M | $1.00M | $-643.00M | $-375.00M | $-5.00M | $-71.00M | $1.00M | $-1.47B | $-219.00M | $-1.31B | $3.00M | $95.00M | $-15.00M | $- | $12.00M | $- | $-90.00M |
Purchases of Investments | $- | $-73.00M | $-66.00M | $-28.00M | $-16.00M | $-63.00M | $-10.00M | $15.00M | $-22.00M | $1.00M | $-15.00M | $51.00M | $-21.00M | $-17.00M | $-13.00M | $-16.00M | $-101.00M | $-27.00M | $-2.00M | $83.00M |
Sales Maturities of Investments | $- | $- | $- | $28.00M | $15.00M | $2.00M | $10.00M | $70.00M | $22.00M | $-2.00M | $32.00M | $-50.00M | $207.00M | $-10.00M | $25.00M | $- | $- | $1.00M | $- | $- |
Other Investing Activities | $-121.00M | $4.00M | $-1.00M | $7.00M | $9.00M | $70.00M | $12.00M | $-63.00M | $18.00M | $76.00M | $11.00M | $74.00M | $22.00M | $133.00M | $39.00M | $28.00M | $122.00M | $50.00M | $28.00M | $54.00M |
Net Cash Used for Investing Activities | $-1.43B | $-271.00M | $-285.00M | $-1.05B | $-197.00M | $-840.00M | $-484.00M | $-183.00M | $-225.00M | $-29.00M | $-1.57B | $-461.00M | $-1.21B | $-133.00M | $71.00M | $-147.00M | $-129.00M | $-59.00M | $-76.00M | $-49.00M |
Debt Repayment | $22.00M | $- | $1.62B | $- | $-41.00M | $37.00M | $- | $- | $-155.00M | $-11.00M | $60.00M | $- | $- | $- | $- | $-260.00M | $-250.00M | $-835.00M | $346.00M | $-990.00M |
Common Stock Issued | $96.00M | $26.00M | $80.00M | $17.00M | $75.00M | $27.00M | $63.00M | $19.00M | $59.00M | $6.00M | $- | $8.00M | $64.00M | $20.00M | $- | $- | $- | $933.00M | $42.00M | $10.00M |
Common Stock Repurchased | $- | $- | $80.00M | $119.00M | $- | $- | $63.00M | $136.00M | $- | $- | $52.00M | $110.00M | $- | $- | $18.00M | $-535.00M | $- | $- | $- | $- |
Dividends Paid | $-23.00M | $- | $- | $- | $- | $-14.00M | $-14.00M | $-13.00M | $-14.00M | $-14.00M | $-14.00M | $-13.00M | $-14.00M | $-14.00M | $-14.00M | $-14.00M | $-14.00M | $- | $- | $- |
Other Financing Activities | $1.58B | $24.00M | $-47.00M | $15.00M | $57.00M | $20.00M | $-55.00M | $14.00M | $-89.00M | $-325.00M | $-104.00M | $5.00M | $20.00M | $16.00M | $-81.00M | $-10.00M | $-44.00M | $1.01B | $-132.00M | $256.00M |
Net Cash Used Provided by Financing Activities | $1.68B | $24.00M | $1.57B | $15.00M | $16.00M | $43.00M | $-69.00M | $1.00M | $-199.00M | $-344.00M | $-6.00M | $-8.00M | $6.00M | $2.00M | $-95.00M | $-819.00M | $-249.00M | $1.10B | $256.00M | $-724.00M |
Effect of Forex Changes on Cash | $-2.00M | $-1.00M | $-7.00M | $4.00M | $-5.00M | $-3.00M | $- | $3.00M | $-6.00M | $-6.00M | $-1.00M | $-1.00M | $-3.00M | $1.00M | $-3.00M | $6.00M | $1.00M | $1.00M | $-9.00M | $12.00M |
Net Change in Cash | $-413.00M | $566.00M | $1.44B | $-77.00M | $512.00M | $-143.00M | $-363.00M | $629.00M | $39.00M | $-71.00M | $-1.64B | $9.00M | $-739.00M | $645.00M | $258.00M | $-287.00M | $266.00M | $1.32B | $93.00M | $-69.00M |
Cash at End of Period | $2.65B | $2.99B | $2.50B | $1.05B | $1.13B | $620.00M | $763.00M | $1.13B | $497.00M | $458.00M | $529.00M | $2.17B | $2.16B | $2.90B | $2.25B | $2.00B | $2.28B | $2.02B | $700.00M | $607.00M |
Cash at Beginning of Period | $3.06B | $2.42B | $1.05B | $1.13B | $620.00M | $763.00M | $1.13B | $497.00M | $458.00M | $529.00M | $2.17B | $2.16B | $2.90B | $2.25B | $2.00B | $2.28B | $2.02B | $700.00M | $607.00M | $676.00M |
Operating Cash Flow | $1.00B | $813.00M | $164.00M | $957.00M | $698.00M | $658.00M | $190.00M | $807.00M | $470.00M | $307.00M | $-58.00M | $478.00M | $465.00M | $643.00M | $284.00M | $673.00M | $643.00M | $269.00M | $-77.00M | $692.00M |
Capital Expenditure | $-304.00M | $-155.00M | $-245.00M | $-267.00M | $-206.00M | $-206.00M | $-121.00M | $-200.00M | $-172.00M | $-105.00M | $-131.00M | $-266.00M | $-107.00M | $-106.00M | $-75.00M | $-159.00M | $-150.00M | $-95.00M | $-102.00M | $-186.00M |
Free Cash Flow | $698.00M | $658.00M | $-81.00M | $690.00M | $492.00M | $452.00M | $69.00M | $607.00M | $298.00M | $202.00M | $-189.00M | $212.00M | $358.00M | $537.00M | $209.00M | $514.00M | $493.00M | $174.00M | $-179.00M | $506.00M |
Boston Scientific Stock Forecast
Analyst ratings, price targets, and earnings estimates for BSX.
BSX Analyst Ratings
Strong Buy
Based on 17 analysts in the past 3 months
BSX Stock 12 Month Forecast
$105.33
Based on 3 analysts in the last 3 months
Recent Price Targets
Recommendation Trends
Analyst Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Latest Price Target Updates
Date | Analyst | Firm | Price Target | Price When Posted | Upside |
---|---|---|---|---|---|
Feb 03, 2025 | Matt O'Brien | Piper Sandler | $115.00 | $103.07 | 11.6% |
Jan 02, 2025 | Vijay Kumar | Evercore ISI | $100.00 | $89.38 | 11.9% |
Dec 30, 2024 | Marie Thibault | BTIG | $101.00 | $89.68 | 12.6% |
Oct 24, 2024 | Shagun Singh | RBC Capital | $98.00 | $87.45 | 12.1% |
Oct 24, 2024 | Kristen Stewart | C.L. King | $90.00 | $87.45 | 2.9% |
Oct 21, 2024 | William Plovanic | Canaccord Genuity | $98.00 | $88.07 | 11.3% |
Oct 18, 2024 | Rick Wise | Stifel Nicolaus | $100.00 | $86.42 | 15.7% |
Oct 15, 2024 | David Rescott | Robert W. Baird | $100.00 | $87.55 | 14.2% |
Oct 14, 2024 | Richard Newitter | Truist Financial | $100.00 | $87.20 | 14.7% |
Sep 19, 2024 | Matt O'Brien | Piper Sandler | $90.00 | $84.23 | 6.9% |
Boston Scientific Dividends
Explore Boston Scientific's dividend history, including dividend yield, payout ratio, and historical payments.
Peers: Medical - Devices
This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.
Company | Market Cap | Price | EPS | P/E Ratio | P/B Ratio |
---|---|---|---|---|---|
![]() Stryker Corporation
SYK
|
$146.98B | $385.18 | $7.86 | $45.83 | $6.65 |
![]() Abbott Laboratories
ABT
|
$226.54B | $130.61 | $3.30 | $33.35 | $4.94 |
![]() Medtronic plc
MDT
|
$119.01B | $92.81 | $2.77 | $28.80 | $2.11 |
![]() DexCom, Inc.
DXCM
|
$34.79B | $89.07 | $1.40 | $88.46 | $23.16 |
![]() Edwards Lifesciences Corporation
EW
|
$44.94B | $76.19 | $2.31 | $32.99 | $6.96 |
![]() Zimmer Biomet Holdings, Inc.
ZBH
|
$20.01B | $100.52 | $0.00 | $0.00 | $0.00 |
![]() |
$- | $ | $ | $ | $ |
![]() ZimVie Inc.
ZIMV
|
$362.65M | $13.14 | $-14.87 | $-1.19 | $1.15 |
![]() STERIS plc
STE
|
$21.55B | $219.34 | $3.83 | $57.73 | $3.46 |
![]() Smith & Nephew plc
SNN
|
$11.21B | $25.70 | $0.30 | $45.15 | $2.28 |
Related Metrics
Explore detailed financial metrics and analysis for BSX.